glp-1
Entity, reached from Hormuz.
- Evidence
- 347 documents · 100 separate publishers
- Standing
- A name from our starting list; its record is kept up to date automatically from coverage
- Time
- first seen 6 Apr 2026, last seen 9 Oct 2026
- Measured
- 23% of mentions say something specific about it; the rest only name it
- As of
- 9 Oct 2026
Where this comes from
- PR Newswire · 2026-10-08 · Victory Square Announces U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Platform (opens the source in a new tab)
- PR Newswire · 2026-10-08 · Hydreight Highlights U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Technology (opens the source in a new tab)
- Medical Daily · 2026-10-08 · GLP-1 Users with Type 2 Diabetes Had 31% Lower Odds of Macular Degeneration Once Health Factors Were Counted (opens the source in a new tab)
- Medical Xpress · 2026-10-07 · Pilot trial suggests structured support may help limit weight regain after GLP-1 treatment (opens the source in a new tab)
- Fierce Pharma · 2026-10-07 · Noom puts a spooky voice to the haunting threat of weight regain for GLP-1 users in new spot (opens the source in a new tab)
- The ASCO Post · 2026-10-07 · GLP-1 Receptor Agonist Use Linked to Lower Colorectal Cancer Risk in Patients With Inflammatory Bowel Disease (opens the source in a new tab)
- Health Policy Watch · 2026-10-07 · GLP-1 Drugs? Surgery? WHO Issues Guidelines for Obesity in Children (opens the source in a new tab)
- PR Newswire · 2026-10-07 · FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body (opens the source in a new tab)
What is claimed about it
- Single source: Reported by one source so far.
- Could not check: We could not count this claim's sources, so we do not say how well it is supported.
- WHO endorses lifestyle changes over GLP-1 drugs in child obesity fight Could not check · a claim about it
- 2026 fda approved weight loss drug retatrutide approval status Could not check · a claim about it
- Victory Square Announces U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Platform Single source · a claim about it
Situations it is named in
Who it moves with
- co-mentioned with eli lilly (96 documents)seen together
- co-mentioned with fda (91 documents)seen together
- co-mentioned with glp-1s (81 documents)seen together
- co-mentioned with studie (79 documents)seen together
- co-mentioned with ai (70 documents)seen together
- co-mentioned with novo nordisk (62 documents)seen together
- co-mentioned with mounjaro (56 documents)seen together